Research programme: diabetes/obesity therapy - Bayer/CuraGen

Drug Profile

Research programme: diabetes/obesity therapy - Bayer/CuraGen

Alternative Names: BAY 76-7171; CT052

Latest Information Update: 17 Apr 2009

Price : $50

At a glance

  • Originator Bayer; CuraGen Corporation
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 17 Apr 2009 No development reported - Preclinical for Diabetes mellitus in USA (PO)
  • 23 Dec 2005 The collaboration agreement between Bayer and CuraGen has been revised
  • 28 Oct 2004 Bayer and CuraGen announced that an orally active, small molecule compound has been advanced into preclinical development for type 2 diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top